Dr. Andreas Harstrick

 

Chief Medical Officer

Dr. Andreas Harstrick is Chief Medical Officer since 2015. He received his MD degree from the University of Hannover in 1986. After spending 12 years in academic medicine at the University of Hannover and the West German Cancer Center in Essen, he moved to the pharmaceutical industry in 1998. He held the position of Senior Vice President (SVP) Oncology Development at Merck Serono from 1998 to 2008. In this function, he had the medical responsibility for all development compounds in oncology and had the medical oversight for the clinical development and registration program of Erbitux in all territories outside of North America. From 2008 to 2014, he was the SVP for Development and Medical Sciences at Imclone. In this function, he was responsible for the design and conduct of all Imclone clinical trials. His major achievements were the design and successful completion of the Phase 3 programs for Ramucirumab and Necitumumab. In addition, he was member of the Imclone/Lilly oncology development board and leader of the Lilly Erbitux team.